https://www.selleckchem.com/pr....oducts/sitravatinib-
ile of alpelisib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative -mutated advanced breast cancer. In SOLAR-1, there was no statistical difference in deterioration of Global Health Status/QoL between arms, whereas symptom subscales favored placebo for diarrhea, appetite loss, nausea or vomiting, and fatigue, known side effects of alpelisib. Treatment decisions must consider efficacy and tolerability; taken with clinical efficacy, these results support the benefit-risk profile of